Schooner Investment Group. Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Schooner Investment Group. reduced its stake in Abbott Laboratories by 33.33% during the most recent quarter end. The investment management company now holds a total of 5,000 shares of Abbott Laboratories which is valued at $225,250 after selling 2,500 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Abbott Laboratories makes up approximately 0.53% of Schooner Investment Group.’s portfolio.

Other Hedge Funds, Including , Central Trust Co boosted its stake in ABT in the latest quarter, The investment management firm added 2,041 additional shares and now holds a total of 170,551 shares of Abbott Laboratories which is valued at $7,683,323. Abbott Laboratories makes up approx 0.56% of Central Trust Co’s portfolio.Harfst Associates boosted its stake in ABT in the latest quarter, The investment management firm added 37,778 additional shares and now holds a total of 45,226 shares of Abbott Laboratories which is valued at $2,046,929. Abbott Laboratories makes up approx 0.78% of Harfst Associates’s portfolio.Clear Harbor Asset Management reduced its stake in ABT by selling 1,100 shares or 9.06% in the most recent quarter. The Hedge Fund company now holds 11,045 shares of ABT which is valued at $499,897. Abbott Laboratories makes up approx 0.11% of Clear Harbor Asset Management’s portfolio.Front Barnett Associates reduced its stake in ABT by selling 213 shares or 1.23% in the most recent quarter. The Hedge Fund company now holds 17,106 shares of ABT which is valued at $768,915. Abbott Laboratories makes up approx 0.15% of Front Barnett Associates’s portfolio.Independent Portfolio Consultants reduced its stake in ABT by selling 280 shares or 8.87% in the most recent quarter. The Hedge Fund company now holds 2,875 shares of ABT which is valued at $121,009. Abbott Laboratories makes up approx 0.04% of Independent Portfolio Consultants’s portfolio.

Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.